Aristotle University Of Thessaloniki
auth.grTotal trials
270
Active
48
Phase 3
2
Total enrollment
46,573
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Goserelin Acetate 3.6 mg inj, implant | — | — | — | — | — | 1 | |
| Benralizumab 30 mg/ml | — | — | — | — | — | 1 | |
| Alendronate Sodium | — | — | — | — | — | 1 | |
| Denosumab | — | — | — | — | 2 | ||
| Mepolizumab 100 MG [Nucala] | — | — | — | — | — | 2 | |
| Ca(OH)2 as intracanal medicament | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
- 2026-03-01
- 2026-07
- 2026-09-12
- 2027-04
Top conditions
- Glaucoma11
- Subfertility8
- Hypertension8
- Mild Cognitive Impairment7
- Coronary Artery Disease6
- Obesity5
- Cardiovascular Diseases5
- Peri-Implantitis4
Frequently asked questions about Aristotle University Of Thessaloniki
- How many clinical trials does Aristotle University Of Thessaloniki have on ClinicalTrials.gov?
- Aristotle University Of Thessaloniki is listed as the lead sponsor on 270 clinical trials in ClinicalTrials.gov, 48 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Aristotle University Of Thessaloniki's trials are in Phase 3?
- 2 of Aristotle University Of Thessaloniki's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Aristotle University Of Thessaloniki focus on?
- Aristotle University Of Thessaloniki's most-studied conditions on ClinicalTrials.gov are Glaucoma, Subfertility, Hypertension, Mild Cognitive Impairment, Coronary Artery Disease.
- When are Aristotle University Of Thessaloniki's next clinical trial readouts?
- Aristotle University Of Thessaloniki has 5 upcoming primary-completion readouts tracked here; the soonest is “BenRalizumab Effect on Airway Remodeling in Severe asTHma”, expected around 2025-12-31.